Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
GLP-1 side effects are real. Nausea, fatigue, and GI symptoms are common in the first weeks. Here's what clinical trials found and how to manage them.
GLP-1 side effects are real, and the gastrointestinal ones are the most common reason people struggle with the medication in the first few weeks. Nausea affects a substantial portion of patients. Vomiting, diarrhea, and constipation are also commonly reported. Most people find these symptoms manageable and see them improve as their body adjusts to the medication. A minority do stop treatment because of side effects. Serious adverse events are less common but exist, and you should know about them before you start. This guide covers what clinical trials have found about the most common GLP-1 side effects, why they happen, and what you can do about them. For anything specific to your situation, your prescribing provider is the right person to ask.
Some programs include more clinical support to help you through the early weeks. Answer 5 questions to get matched.
Take the free quiz →Nausea is the most frequently reported GLP-1 side effect. In the STEP 1 trial of semaglutide 2.4mg (Wegovy), nausea was reported by approximately 44% of participants in the semaglutide group compared with 16% in the placebo group (NEJM, 2021). For tirzepatide (Zepbound), the FDA prescribing label — which draws from SURMOUNT-1 and related weight-loss trials — reports nausea in approximately 25–29% of patients depending on dose (Zepbound prescribing information, FDA).
It tends to be worst in the first four to eight weeks, particularly after a dose increase. Most patients report it improving substantially once they've been on a stable dose for a few weeks.
Practical tips: eat smaller, more frequent meals; avoid greasy or high-fat foods, especially right after your injection day; eat slowly and stop before you feel full; and stay upright for at least 30 minutes after eating. If nausea is severe or persistent, contact your prescribing provider before your next injection.
Vomiting is less common than nausea. In STEP 1, vomiting was reported in approximately 24% of the semaglutide group versus 6% in placebo (NEJM, 2021). Most episodes are occasional rather than frequent, and they follow a similar pattern to nausea: more common early on, improving with time on a stable dose.
If vomiting is frequent enough to affect your ability to eat or drink normally, reach out to your provider. Dehydration from vomiting is something to take seriously.
Diarrhea was reported in roughly 30% of semaglutide patients in the STEP 1 trial (NEJM, 2021). Like the other GI symptoms, it typically clusters in the early weeks. Staying well hydrated helps. Avoid high-fat and high-fiber foods if diarrhea is ongoing, and again, let your provider know if it's affecting your daily function.
Constipation may seem like the opposite problem from diarrhea, but both are commonly reported with GLP-1 medications. Because these drugs slow how fast food moves through your digestive tract, constipation is a predictable consequence for some people. In the STEP 1 trial, constipation was reported in approximately 24% of the semaglutide group versus 11% in the placebo group (NEJM, 2021). Increasing water intake and dietary fiber (if tolerated) may help. Discuss with your provider before adding any laxatives or supplements.
Fatigue in the first few weeks is reported by some patients, though it is less studied than the GI symptoms in the published trial data. The mechanism is not fully established, but reduced caloric intake, the body's adjustment to the medication, and any nausea-related disruption to eating can all contribute. It typically eases as appetite and eating patterns stabilize. If fatigue is severe or lasting, tell your provider.
The short answer: GLP-1 receptors are found throughout the gastrointestinal tract, not just in the pancreas. When a GLP-1 medication activates these receptors, it slows gastric emptying, meaning food moves more slowly from the stomach into the small intestine. This is part of how the medication reduces appetite and helps regulate blood sugar (FDA prescribing information for Wegovy). Slower gastric emptying means your stomach stays fuller longer, which is useful for weight management but can also produce a prolonged sensation of fullness that tips into nausea.
This is normal physiology. Nausea in the early weeks is not a sign that something has gone wrong or that the medication is harming you. It is the GLP-1 receptors in your gut doing exactly what they are designed to do, and your body adapting to a new level of stimulation. The adaptation takes time.
The side effects above affect a large portion of patients but are generally manageable. A separate category of adverse events is rarer but requires prompt attention.
Pancreatitis. Acute pancreatitis has been reported in patients taking GLP-1 medications. The FDA prescribing information for semaglutide notes that pancreatitis should be considered if a patient develops severe, persistent abdominal pain (FDA prescribing information for Wegovy). If you experience severe abdominal pain that does not resolve, stop the medication and seek medical care immediately. Do not wait for your next scheduled provider check-in.
Gallbladder disease. Gallstones and cholecystitis (gallbladder inflammation) have been reported with GLP-1 use. Rapid weight loss in general is a known risk factor for gallstone formation, and GLP-1 medications may contribute (FDA prescribing information for Wegovy). Tell your provider if you experience upper right abdominal pain, nausea with fever, or yellowing of the skin or eyes.
Heart rate increase. A small mean increase in resting heart rate has been observed with semaglutide in clinical trials (FDA prescribing information for Wegovy). For most patients this is not clinically significant, but if you have underlying heart conditions, discuss this with your cardiologist or prescribing provider before starting.
Thyroid C-cell tumors (black box warning). The FDA prescribing information for semaglutide and tirzepatide includes a black box warning about thyroid C-cell tumors based on studies in rodents (FDA prescribing information for Wegovy). To be direct about what this means: the tumors were observed in rodents at doses used in animal studies; they have not been observed in humans in the clinical trial data to date. The warning reflects regulatory caution, not a confirmed human risk. Still, these medications are not recommended for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2). Your provider should screen for this before prescribing.
Most of these strategies come down to giving your body time to adjust and reducing the load on your digestive system during that adjustment period. None of the following replaces guidance from your healthcare provider, but they are consistent with what most prescribing clinicians recommend.
Eat smaller meals. A full stomach on a GLP-1 medication feels more full than you're used to. Eating smaller portions more frequently is easier on your GI system than large meals.
Avoid high-fat foods, especially around injection day. Fatty foods slow gastric emptying on their own, and stacking that effect on top of the medication's effects can intensify nausea. Many patients find this is most important in the 24 hours after their injection.
Stay hydrated. This matters especially if you're experiencing nausea, vomiting, or diarrhea. Consistent water intake throughout the day is more helpful than large amounts at once.
Don't rush dose escalation. The standard escalation schedules for semaglutide and tirzepatide are graduated for a reason: slower dose increases give your body more time to adapt. Clinical trial protocols typically move patients up in dose every four weeks. If you are experiencing significant side effects at your current dose, talk to your provider about whether staying at that dose longer before escalating makes sense for you.
Inject on the same day each week. Consistency helps your body anticipate the effect. Some patients time their injection for a day when they have a lighter schedule in case the first 24 hours are uncomfortable.
Some symptoms are clear signals to contact your provider without waiting.
If in doubt, call. Your provider would rather hear from you than have you wait out a symptom that needs attention.
Both medications share a similar GI side effect profile because both act on GLP-1 receptors in the gut. Tirzepatide (Zepbound, Mounjaro) is a dual GIP/GLP-1 receptor agonist, meaning it activates an additional receptor pathway. Comparing across separate trials — STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide — nausea rates appear somewhat lower with tirzepatide, though the trials used different populations and protocols, so this is an inference rather than a head-to-head finding (SURMOUNT-1, NEJM 2022; STEP 1, NEJM 2021). In practice, patients report meaningful individual variation in tolerability with both medications. If you try one and find the side effects difficult, it is worth discussing the other option with your provider.
Pros
Cons
Ro
$295–$494/month (per Ro website, April 2026)
Insurance coordination built in, plus an educational program to support you through early weeks.
Found
$129/mo membership + medication (compounded semaglutide ~$189/mo, per Found website, April 2026)
Licensed clinicians, health coaches, and a behavior change app — full support from week one.
Side effects are a real part of starting a GLP-1 medication. For most people who stay with the medication, they improve significantly after the first few weeks. The patients who navigate this period best tend to be the ones who have a clear sense of what to expect, go slowly on dose escalation, and have a provider they can reach when something feels wrong.
GLP-1 medications require a prescription from a licensed healthcare provider. This article is for informational purposes only and does not constitute medical advice. It does not diagnose conditions or recommend specific treatments. Always consult your healthcare provider about any symptoms you experience on a GLP-1 medication, including those described in this article.